- AU$167.96m
- AU$160.46m
- AU$27.77m
- 54
- 35
- 63
- 52
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 103.96 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 1.37% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.21 | ||
| Price to Tang. Book | 6.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.05 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.67% | ||
| Return on Equity | -13.67% | ||
| Operating Margin | -14.31% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 14.1 | 14.68 | 17.85 | 24.96 | 27.77 | 37.38 | 60.9 | 15.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyclopharm Limited is an Australia-based health technology company. The Company’s principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. Its subsidiaries include Cyclomedica Europe Limited, Cyclomedica Australia Pty Limited and Cyclomedica Canada Limited.
Directors
- David Heaney NEC
- Mathew Farag COO
- James McBrayer MDR
- Lynn McLauchlin GMG
- Caryn Cheah CTR
- Sally-Ann Cornelius OTH
- Mark Doverty OTH
- Niamh McAree OTH
- Graham Phillips OTH
- Chris Quinn OTH
- Dianne Angus NED
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 31st, 2005
- Public Since
- January 18th, 2007
- No. of Shareholders
- 1,623
- No. of Employees
- 87
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 94,096,326
- Address
- Unit 4 / 1 The Crescent, Kingsgrove, SYDNEY, 2208
- Web
- https://www.cyclopharm.com/
- Phone
- +61 295410411
- Auditors
- Nexia Sydney Audit Pty Limited
Upcoming Events for CYC
Half Year 2024 Cyclopharm Ltd Earnings Release
Similar to CYC
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Cyclopharm share price?
As of Today at 19:06 UTC, shares in Cyclopharm are trading at AU$1.79. This share price information is delayed by 15 minutes.
How has the Cyclopharm share price performed this year?
Shares in Cyclopharm last closed at AU$1.79 and the price had moved by -7.03% over the past 365 days. In terms of relative price strength the Cyclopharm share price has underperformed the ASX All Ordinaries Index by -13.4% over the past year.
What are the analyst and broker recommendations for Cyclopharm?
The overall consensus recommendation for Cyclopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cyclopharm dividend yield?
Cyclopharm does not currently pay a dividend.
Does Cyclopharm pay a dividend?
Cyclopharm does not currently pay a dividend.
When does Cyclopharm next pay dividends?
Cyclopharm does not currently pay a dividend.
How do I buy Cyclopharm shares?
To buy shares in Cyclopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyclopharm?
As of the previous close price of AU$1.79, shares in Cyclopharm had a market capitalisation of AU$167.96m.
Where are Cyclopharm shares listed?
Here are the trading details for Cyclopharm:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CYC
What kind of share is Cyclopharm?
Based on an overall assessment of its quality, value and momentum Cyclopharm is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyclopharm share price forecast for 2024?
The analyst consensus target price for shares in Cyclopharm is AU$3.80. That is 112.89% above the last closing price of AU$1.79.
Analysts covering Cyclopharm currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.03 for the next financial year.
What is the trend in the Cyclopharm share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyclopharm. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -33.54%.
As of the last closing price of AU$1.79, shares in Cyclopharm were trading -15.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyclopharm PE Ratio?
The Cyclopharm PE ratio based on its reported earnings over the past 12 months is 103.96. The shares last closed at AU$1.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyclopharm?
Cyclopharm's management team is headed by:
- David Heaney - NEC
- Mathew Farag - COO
- James McBrayer - MDR
- Lynn McLauchlin - GMG
- Caryn Cheah - CTR
- Sally-Ann Cornelius - OTH
- Mark Doverty - OTH
- Niamh McAree - OTH
- Graham Phillips - OTH
- Chris Quinn - OTH
- Dianne Angus - NED